WEDNESDAY, May 15, 2024 -- Dupilumab monotherapy is efficacious and safe for patients with atopic hand and/or foot dermatitis, according to a study published in the June issue of the Journal of the American Academy of Dermatology.

Eric L. Simpson, M.D., from the Oregon Health & Science University in Portland, and colleagues examined the efficacy and safety of dupilumab in atopic hand and/or foot dermatitis in a phase 3 study involving adults and adolescents with moderate-to-severe atopic dermatitis (106 adults and 27 adolescents). Participants were randomly assigned to dupilumab monotherapy or matched placebo (67 and 66 patients, respectively). The proportion of patients achieving a Hand and Foot Investigator's Global Assessment score of 0 or 1 at week 16 was examined as the primary end point.

The researchers found that significantly more patients receiving dupilumab versus placebo achieved a Hand and Foot Investigator's Global Assessment score of 0 or 1 (27 versus 11 [40.3 versus 16.7 percent]). All other prespecified end points were met and safety was consistent with the known atopic dermatitis dupilumab profile.

"This study supports dupilumab as a novel efficacious systemic therapy for moderate-to-severe atopic hand and/or foot dermatitis," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Sanofi and Regeneron, which manufacture dupilumab and funded the study.